| Malignant neoplasm of breast
Verzenio vs Herceptin
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Verzenio vs Herceptin with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHerceptin has a higher rate of injection site reactions vs Verzenio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Herceptin but not Verzenio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Verzenio
Herceptin
At A Glance
Oral
Twice daily
CDK4/6 inhibitor
IV infusion
Weekly or every 3 weeks
HER2 antagonist
Indications
- Malignant neoplasm of breast
- Carcinoma breast stage IV
- Malignant neoplasm of breast
- Gastric Adenocarcinoma
- Adenocarcinoma of the gastroesophageal junction
Dosing
Malignant neoplasm of breast 150 mg orally twice daily in combination with tamoxifen or an aromatase inhibitor for 2 years as adjuvant treatment (or until disease recurrence or unacceptable toxicity).
Carcinoma breast stage IV 150 mg orally twice daily in combination with an aromatase inhibitor (initial therapy) or fulvestrant (after endocrine therapy progression); 200 mg orally twice daily as monotherapy (after endocrine therapy and prior chemotherapy); continue until disease progression or unacceptable toxicity.
Malignant neoplasm of breast (adjuvant) Schedule 1: 4 mg/kg loading dose over 90 min IV, then 2 mg/kg weekly over 30 min for 12 or 18 weeks, then 6 mg/kg every 3 weeks to complete 52 weeks; Schedule 2: 8 mg/kg loading dose over 90 min IV, then 6 mg/kg every 3 weeks for 52 weeks.
Malignant neoplasm of breast (metastatic) 4 mg/kg loading dose as 90-min IV infusion, then 2 mg/kg weekly as 30-min IV infusions until disease progression.
Gastric Adenocarcinoma, Adenocarcinoma of the gastroesophageal junction 8 mg/kg loading dose over 90-min IV infusion, then 6 mg/kg over 30-90 min IV every 3 weeks until disease progression, in combination with cisplatin and capecitabine or 5-fluorouracil.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, alopecia, thrombocytopenia
Serious neutropenia, diarrhea, interstitial lung disease/pneumonitis, hepatotoxicity, venous thromboembolism
Postmarketing interstitial lung disease/pneumonitis
Most common Fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, myalgia
Serious Cardiomyopathy, infusion reactions, embryo-fetal toxicity, pulmonary toxicity, exacerbation of chemotherapy-induced neutropenia
Postmarketing Infusion reaction, oligohydramnios, glomerulopathy, immune thrombocytopenia, tumor lysis syndrome
Pharmacology
Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6); in ER-positive breast cancer cells, it blocks Rb phosphorylation and cell cycle progression from G1 into S phase, resulting in senescence and apoptosis.
Humanized IgG1 kappa monoclonal antibody (anti-HER2) that inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) preferentially on HER2-overexpressing cancer cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Verzenio
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Herceptin
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (1/12) · Qty limit (0/12)
UnitedHealthcare
Verzenio
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Herceptin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Verzenio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Herceptin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Herceptin.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VerzenioView full Verzenio profile
HerceptinView full Herceptin profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.